Relypsa (RLYP) : Traders are bullish on Relypsa (RLYP) as it has outperformed the S&P 500 by a wide margin of 52.99% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.01%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.06% in the last 1 week, and is up 54.57% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.93% and the 50-Day Moving Average is 38.01%. Relypsa (NASDAQ:RLYP): On Fridays trading session , Opening price of the stock was $31.98 with an intraday high of $31.98. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $31.95. However, the stock managed to close at $31.95, a loss of 0.13% for the day. On the previous day, the stock had closed at $31.99. The total traded volume of the day was 1,073,755 shares.
The company Insiders own 3.7% of Relypsa shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -34.03% . Institutional Investors own 81.42% of Relypsa shares. During last six month period, the net percent change held by insiders has seen a change of 71.72%. Also, Equity analysts at the Brokerage firm Oppenheimer terminates its rating on Relypsa (NASDAQ:RLYP). Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on August 9, 2016.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Companys lead product candidate, Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA. The Companys NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials, four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment, or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.